CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 3,345,000 SHARES, WITH ACCUMULATED PURCHASE TOTALLING 7,529,500 SHARES
CSTONE PHARMA-B: ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023
CSTONE PHARMA-B: 2023 ANNUAL REPORT
CSTONE PHARMA-B: PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE ACCEPTANCE OF RET INHIBITOR GAVRETO (PRALSETINIB) MANUFACTURING LOCALIZATION APPLICATION BY CENTER FOR DRUG EVALUATION OF CHINA NMPA
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024
CSTONE PHARMA-B: (I) GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME; AND (II) GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP
CSTONE PHARMA-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE FIFTH INDICATION APPROVED FOR SUGEMALIMAB IN CHINA AS FIRST-LINE TREATMENT OF GASTRIC CANCER
CSTONE PHARMA-B: DATE OF BOARD MEETING
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2024
CSTONE PHARMA-B: LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS
CSTONE PHARMA-B: LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS
CSTONE PHARMA-B: POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 17, 2024
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023
CSTONE PHARMA-B: FORM OF PROXY FOR EXTRAORDINARY GENERAL MEETING
CSTONE PHARMA-B: NOTICE OF EXTRAORDINARY GENERAL MEETING
CSTONE PHARMA-B: (1) PROPOSED GRANT OF OPTIONS TO A DIRECTOR AND CHIEF EXECUTIVE OFFICER UNDER THE POST-IPO ESOP; (2) NOTICE OF EXTRAORDINARY GENERAL MEETING; AND (3) CLOSURE OF REGISTER OF MEMBERS FOR THE EXTRAORDINARY GENERAL MEETING
No Data